Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313410123> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4313410123 endingPage "15" @default.
- W4313410123 startingPage "8" @default.
- W4313410123 abstract "Purpose: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD). Methods: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2 mg (HD combo), or IAI 2 mg at baseline, week 4, and week 8. The LD combo was continued every 8 weeks (q8w). At week 12, the HD combo was re-randomized to q8w or every 12 weeks (q12w) and IAI was re-randomized to q8w, q12w, or HD combo q8w through week 32. Results: The study comprised 365 eyes. At week 12, the mean best-corrected visual acuity (BCVA) gains from baseline were similar in the LD combo group, HD combo group, and IAI group (5.2 letters, 5.6 letters, and 5.4 letters, respectively); the mean central subfield thickness (CST) reductions were similar (182.2 µm, 200.0 µm, and 178.6 µm, respectively). The mean changes in BCVA and CST through week 36 were similar across groups. At week 12, complete retinal fluid resolution was observed in 49.1% (LD combo), 50.8% (HD combo), and 43.6% (IAI) of eyes; the proportions with a CST of 300 μm or less were similar across groups. Numerical trends at week 32 toward complete retinal fluid resolution with combination treatment were not maintained at week 36. Serious ocular adverse events were infrequent and comparable across groups. Conclusions: In nAMD, nesvacumab + aflibercept showed no additional BCVA or CST benefit over IAI monotherapy." @default.
- W4313410123 created "2023-01-06" @default.
- W4313410123 creator A5020453219 @default.
- W4313410123 creator A5022217015 @default.
- W4313410123 creator A5022551584 @default.
- W4313410123 creator A5028848967 @default.
- W4313410123 creator A5030449236 @default.
- W4313410123 creator A5034787608 @default.
- W4313410123 creator A5047370210 @default.
- W4313410123 creator A5058044536 @default.
- W4313410123 creator A5061673504 @default.
- W4313410123 creator A5065670758 @default.
- W4313410123 creator A5082845184 @default.
- W4313410123 creator A5083062288 @default.
- W4313410123 creator A5086955368 @default.
- W4313410123 date "2022-12-30" @default.
- W4313410123 modified "2023-10-01" @default.
- W4313410123 title "Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial" @default.
- W4313410123 cites W1481978003 @default.
- W4313410123 cites W1968189763 @default.
- W4313410123 cites W2004117352 @default.
- W4313410123 cites W2043208670 @default.
- W4313410123 cites W2068742492 @default.
- W4313410123 cites W2085712747 @default.
- W4313410123 cites W2124415048 @default.
- W4313410123 cites W2128154767 @default.
- W4313410123 cites W2128210855 @default.
- W4313410123 cites W2163616867 @default.
- W4313410123 cites W2170000965 @default.
- W4313410123 cites W2171979478 @default.
- W4313410123 cites W2202644973 @default.
- W4313410123 cites W2531065411 @default.
- W4313410123 cites W2616502721 @default.
- W4313410123 cites W2737926042 @default.
- W4313410123 cites W4221012768 @default.
- W4313410123 cites W4225470058 @default.
- W4313410123 doi "https://doi.org/10.1177/24741264221126061" @default.
- W4313410123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37008402" @default.
- W4313410123 hasPublicationYear "2022" @default.
- W4313410123 type Work @default.
- W4313410123 citedByCount "0" @default.
- W4313410123 crossrefType "journal-article" @default.
- W4313410123 hasAuthorship W4313410123A5020453219 @default.
- W4313410123 hasAuthorship W4313410123A5022217015 @default.
- W4313410123 hasAuthorship W4313410123A5022551584 @default.
- W4313410123 hasAuthorship W4313410123A5028848967 @default.
- W4313410123 hasAuthorship W4313410123A5030449236 @default.
- W4313410123 hasAuthorship W4313410123A5034787608 @default.
- W4313410123 hasAuthorship W4313410123A5047370210 @default.
- W4313410123 hasAuthorship W4313410123A5058044536 @default.
- W4313410123 hasAuthorship W4313410123A5061673504 @default.
- W4313410123 hasAuthorship W4313410123A5065670758 @default.
- W4313410123 hasAuthorship W4313410123A5082845184 @default.
- W4313410123 hasAuthorship W4313410123A5083062288 @default.
- W4313410123 hasAuthorship W4313410123A5086955368 @default.
- W4313410123 hasBestOaLocation W43134101231 @default.
- W4313410123 hasConcept C118487528 @default.
- W4313410123 hasConcept C141071460 @default.
- W4313410123 hasConcept C168563851 @default.
- W4313410123 hasConcept C2776403814 @default.
- W4313410123 hasConcept C2776694085 @default.
- W4313410123 hasConcept C2777802072 @default.
- W4313410123 hasConcept C2778257484 @default.
- W4313410123 hasConcept C2778749236 @default.
- W4313410123 hasConcept C2780827179 @default.
- W4313410123 hasConcept C71924100 @default.
- W4313410123 hasConceptScore W4313410123C118487528 @default.
- W4313410123 hasConceptScore W4313410123C141071460 @default.
- W4313410123 hasConceptScore W4313410123C168563851 @default.
- W4313410123 hasConceptScore W4313410123C2776403814 @default.
- W4313410123 hasConceptScore W4313410123C2776694085 @default.
- W4313410123 hasConceptScore W4313410123C2777802072 @default.
- W4313410123 hasConceptScore W4313410123C2778257484 @default.
- W4313410123 hasConceptScore W4313410123C2778749236 @default.
- W4313410123 hasConceptScore W4313410123C2780827179 @default.
- W4313410123 hasConceptScore W4313410123C71924100 @default.
- W4313410123 hasFunder F4320307771 @default.
- W4313410123 hasFunder F4320311600 @default.
- W4313410123 hasIssue "1" @default.
- W4313410123 hasLocation W43134101231 @default.
- W4313410123 hasLocation W43134101232 @default.
- W4313410123 hasLocation W43134101233 @default.
- W4313410123 hasOpenAccess W4313410123 @default.
- W4313410123 hasPrimaryLocation W43134101231 @default.
- W4313410123 hasRelatedWork W1459148225 @default.
- W4313410123 hasRelatedWork W2015993450 @default.
- W4313410123 hasRelatedWork W2320987231 @default.
- W4313410123 hasRelatedWork W2522975619 @default.
- W4313410123 hasRelatedWork W2601742736 @default.
- W4313410123 hasRelatedWork W2606465891 @default.
- W4313410123 hasRelatedWork W2745923716 @default.
- W4313410123 hasRelatedWork W2769959318 @default.
- W4313410123 hasRelatedWork W2912568837 @default.
- W4313410123 hasRelatedWork W3122143690 @default.
- W4313410123 hasVolume "7" @default.
- W4313410123 isParatext "false" @default.
- W4313410123 isRetracted "false" @default.
- W4313410123 workType "article" @default.